Showing 3411-3420 of 5773 results for "".
- Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of RP Associated with Usher Syndromehttps://modernod.com/news/nacuity-pharmaceuticals-achieves-target-enrollment-for-phase-12-clinical-trial-of-npi-001-for-the-treatment-of-rp-associated-with-usher-syndrome/2481641/Nacuity Pharmaceuticals announced that target enrollment of 48 patients has been reached in the SLO-RP phase 1/2 clinical trial of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). “We are pleased to reach our target enrollment,
- Thea Pharma Launches Preservative Freedom Coalition to Advocate for Preservative-Free Eye Carehttps://modernod.com/news/thea-pharma-launches-preservative-freedom-coalition-to-advocate-for-preservative-free-eye-care/2481639/Thea Pharma announced the launch of the "Preservative Freedom Coalition," which aims to raise awareness of unmet needs in ocular surface disease and opportunities to pursue preservative-free topical ophthalmic medications. In addition to Thea, founding members of the brand-agn
- NEI Explores Potential Impacts of Climate Change on Eye Healthhttps://modernod.com/news/nei-explores-potential-impacts-of-climate-change-on-eye-health/2481635/The National Eye Institute (NEI) convened a panel of experts on April 26, 2023, at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to discuss teye health care needs of the future, including the potential effects of a changing climate on eye health a
- Norlase Secures $11M in New Funding Following Regulatory Clearance of ECHO Pattern Laserhttps://modernod.com/news/norlase-secures-11m-in-new-funding-following-regulatory-clearance-of-echo-pattern-laser/2481634/Norlase announced it has secured $11 million in funding, its largest investment round thus far. Norlase said the funding will enable it to accelerate the production ramp-up of the ECHO pattern laser, which just received FDA clearance and CE Mark earlier this month, as well as
- Alimera Completes Recruitment for Its NEW DAY Study Evaluating Iluvien for DMEhttps://modernod.com/news/alimera-completes-recruitment-for-its-landmark-new-day-study/2481633/Alimera Sciences announced that it has completed enrollment for the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone acetonide intravitreal implant, 0.19mg) as a baseline therapy in p
- Partnership Agreement Between Mireca and Graybug Terminatedhttps://modernod.com/news/partnership-agreement-between-mireca-and-graybug-terminated/2481631/Mireca Medicines announced that the partnership agreement between Mireca and Graybug (now CalciMedica) has been terminated due to a shift in drug development focus of CalciMedica away from ocular diseases. As part of the termination, all intellectual property rights that
- Sight Sciences: Two Year Study Results Show Sustained Reductions in IOP and Glaucoma Medication Use with Omni Treatmenthttps://modernod.com/news/sight-sciences-two-year-study-results-show-sustained-reductions-in-iop-and-glaucoma-medication-use-in-mild-moderate-poag-patients-treated-with-omni/2481630/Sight Sciences announced the publication of 2-year results of the ROMEO (Retrospective, Observational, Multicenter, Evaluation of OMNI) study in Clinical Ophthalmology. The longest multicenter study of the Omni Surgical System technology to date in both standalone and comb
- FDA Approves Bausch + Lomb and Novaliq's Miebo for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-approval-of-miebotm-perfluorohexyloctane-ophthalmic-solution-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2481625/Bausch + Lomb announced on Thursday that the FDA has approved Miebo (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) for the treatment of the signs and symptoms of dry eye disease (DED). The comapnies say Miebo is the first and only FDA-approved treatment fo
- Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapieshttps://modernod.com/news/ray-therapeutics-closes-oversubscribed-100m-series-a-financing-to-advance-optogenetic-gene-therapies/2481621/Ray Therapeutics announced an upsized and oversubscribed $100 million Series A financing round to advance multiple programs targeting blinding diseases through clinical development. Ray Therapeutics has developed an optogenetic platform to bioengineer a pipeline of g
- Invirsa Completes Enrollment of Phase 1/2a Dry Eye Studyhttps://modernod.com/news/invirsa-completes-enrollment-of-phase-12a-dry-eye-study/2481619/Invirsa announced that its first clinical trial, a phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eye drop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tol